Overview of REXULTI
REXULTI, with the active ingredient brexpiprazole, is a prescription medication marketed by Otsuka America Pharmaceutical, Inc. It is often used in conjunction with other medications to treat major depressive disorder and as an adjunctive treatment for schizophrenia[5].
Current Pricing
As of the latest data available in 2024, the average pharmacy cost for REXULTI 0.25 MG tablets, identified by the NDC code 59148-0035-13, is approximately $47.03524 per unit[5].
Market Trends
Pharmaceutical Industry Growth
The pharmaceutical industry is expected to see steady growth in the coming years. Global pharmaceutical output is forecasted to increase by 3% in 2024, 4% in 2025, and 3.6% in 2026, driven by factors such as ageing populations, emerging markets, and new product demand[3].
Drug Price Inflation
Vizient, Inc. projects a drug price inflation rate of 3.81% for 2025, which could impact the pricing of REXULTI and other pharmaceuticals. This inflation is partly due to the expanding indications of previously approved medications and the introduction of high-cost therapies[2].
Regional Market Dynamics
United States
In the U.S., pharmaceutical output is expected to increase by 2.9% in 2024 and 2.5% in 2025. The demand for medications, including those for chronic conditions and weight loss, is driven by an ageing population. However, drug pricing regulations could impact the industry, potentially affecting the prices of branded pharmaceuticals like REXULTI[3].
Global Demand
Globally, regions like the Asia Pacific and the Middle East are expected to have the largest annual growth rates. China, in particular, is seeing significant growth in pharmaceutical production, supported by government investments in R&D and a growing middle class demanding high-value-added drugs[3].
Price Projections
Given the overall trends in the pharmaceutical industry, here are some key points to consider for price projections:
General Inflation
With an expected drug price inflation rate of 3.81% for 2025, it is likely that the price of REXULTI will increase accordingly. This means the price per unit could rise to around $48.73 by the end of 2025, assuming a consistent inflation rate[2].
Market Competition
The pricing of REXULTI could also be influenced by market competition. As new drugs and therapies enter the market, there may be pressure to adjust prices to remain competitive. However, since REXULTI is a branded medication, it is likely to maintain its premium pricing unless significant generic competition emerges[5].
Regulatory Impact
Regulatory changes aimed at reducing pharmaceutical prices could impact the pricing strategy for REXULTI. If such regulations are implemented, the price might stabilize or even decrease, but this is speculative and depends on the specific policies enacted[3].
Key Takeaways
- Current Pricing: As of 2024, the average pharmacy cost for REXULTI 0.25 MG tablets is approximately $47.03524 per unit.
- Market Growth: The pharmaceutical industry is expected to grow, driven by ageing populations and new product demand.
- Price Inflation: A projected 3.81% drug price inflation rate for 2025 could increase the price of REXULTI.
- Regulatory Impact: Potential regulatory changes could affect pricing strategies for branded pharmaceuticals.
FAQs
Q: What is the current price of REXULTI 0.25 MG tablets?
A: As of 2024, the average pharmacy cost for REXULTI 0.25 MG tablets is approximately $47.03524 per unit.
Q: What factors are driving the growth of the pharmaceutical industry?
A: The growth is driven by ageing populations, emerging markets, and new product demand.
Q: How might drug price inflation affect REXULTI prices in 2025?
A: With a projected 3.81% drug price inflation rate, the price of REXULTI could increase to around $48.73 by the end of 2025.
Q: Could regulatory changes impact the price of REXULTI?
A: Yes, regulatory changes aimed at reducing pharmaceutical prices could potentially stabilize or decrease the price of REXULTI.
Q: What regions are expected to see the largest growth in pharmaceutical output?
A: The Asia Pacific and the Middle East are expected to have the largest annual growth rates in pharmaceutical output.
Sources
- PharmaCompass.com - NDC Code 59148-045-80 - Aripiprazole
- Vizient, Inc. - Vizient projects drug price inflation at 3.81%
- Atradius - Industry Trends Pharmaceuticals September 2024
- DrugDev.com - NSCLC MARKET - Global Drug Forecast & Market Analysis to 2025
- DrugPatentWatch.com - Pharmaceutical drug prices and trends for REXULTI
